16 research outputs found
PCN22 EFFICACY AND CARDIAC SAFETY OF TRASTUZUMAB (T) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY-STAGE BREAST CANCER: A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
PCN5 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: AN UPDATE OF THE PREVIOUSLY PUBLISHED SYSTEMATIC REVIEW AND META-ANALYSIS
PCN24 EFFICACY OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE (GEM) COMPARED TO SURGERY-ONLY IN PATIENTS WITH RESECTED PANCREATIC CANCER: SYSTEMATIC REVIEW (SR) AND METAANALYSIS (MA)
CN1 EFFICACY OF THE COMBINATION BEVACIZUMAB PLUS CHEMOTHERAPY (BEV-CT) COMPARED TO CT ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
PCN22 EFFICACY AND CARDIAC SAFETY OF TRASTUZUMAB (T) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY-STAGE BREAST CANCER: A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
CN1 EFFICACY OF THE COMBINATION BEVACIZUMAB PLUS CHEMOTHERAPY (BEV-CT) COMPARED TO CT ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
PCN24 EFFICACY OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE (GEM) COMPARED TO SURGERY-ONLY IN PATIENTS WITH RESECTED PANCREATIC CANCER: SYSTEMATIC REVIEW (SR) AND METAANALYSIS (MA)
PCN5 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: AN UPDATE OF THE PREVIOUSLY PUBLISHED SYSTEMATIC REVIEW AND META-ANALYSIS
Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report
Estudo das freqüências dos principais fatores de risco para acidente vascular cerebral isquêmico em idosos Study of the main risk factors frequencies for ischemic cerebrovascular disease in elderly patients
Foram estudados retrospectivamente 262 pacientes com diagnóstico clínico de acidente vascular cerebral isquêmico (AVCi) permanente, com idade igual ou superior a 60 anos, selecionados dos 1015 registros da Liga de Aterosclerose da Clínica Neurológica da ISCMSP, de 1990 a 2002. O estudo focalizou as freqüências dos fatores de risco modificáveis para AVCi nesta população idosa, considerando-se sexo e faixa etária dos pacientes. Os resultados evidenciaram que a hipertenção arterial sistêmica é significativamente freqüente (87,8%) entre pacientes idosos com AVCi, independentemente do sexo e da faixa etária. Tabagismo (46,9%) e etilismo (35,1%) revelaram-se fatores de riscos modificáveis freqüentes especialmente entre os homens. As cardiopatias (27,0%), o Diabete Melito (19,9%) e as dislipidemias (15,6%) também se revelaram fatores de risco modificáveis freqüentes em pacientes idosos com AVCi, em ambos os sexos e em ambas as faixas etárias estudadas (60 a 70 anos e mais que 71 anos). Foi relativamente baixa a freqüência de hiperuricemia nesta amostra.<br>Two hundred and sixty two patients with clinical diagnosis of permanent ischemic stroke, all of them aged 60 or more were retrospectively studied from the 1015 cerebrovascular diseases (CVD) records of the Atherosclerosis Ligue of the Neurology Clinics of the ISCMSP, from 1990 to 2002. The study emphasized modifiable risk factors frequencies for ischemic stroke in this population, considering gender and age of the patients. Results have evidenced that systemic arterial hypertension is a main risk factor significantly frequent in old people (87.8%), independently of gender and age. Smoking (46.9%) and alcohol consumption (35.1%) have revealed to be very frequent important modifiable risk factors especially among men. Lower frequencies have been presented for cardiac diseases (27.0%), Diabetes Melitus (19.9%), and dislipidemia (15.6%) as risk factors for ischemic stroke in old people of both genders and all ages after 60. There was relatively low frequency of hiperuricemia in this set of patients
